Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Has the South Korean Life Sciences Industry valuation changed over the past few years?
|Wed, 19 Jan 2022||₩60.6t||₩2.3t||₩412.7b||25.3x|
|Fri, 17 Dec 2021||₩71.5t||₩2.3t||₩412.7b||29.5x|
|Sun, 14 Nov 2021||₩62.0t||₩2.1t||₩329.9b||25x|
|Tue, 12 Oct 2021||₩61.9t||₩2.1t||₩329.9b||26.2x|
|Thu, 09 Sep 2021||₩68.8t||₩2.2t||₩330.9b||36x|
|Sat, 07 Aug 2021||₩69.5t||₩2.2t||₩336.8b||35.5x|
|Fri, 30 Apr 2021||₩62.1t||₩2.1t||₩247.5b||38.5x|
|Mon, 01 Feb 2021||₩61.2t||₩2.0t||₩213.0b||58.3x|
|Thu, 05 Nov 2020||₩52.3t||₩1.8t||₩306.1b||36.4x|
|Sun, 09 Aug 2020||₩55.1t||₩1.7t||₩273.1b||72.6x|
|Sat, 02 May 2020||₩42.6t||₩1.4t||₩209.9b||69x|
|Tue, 04 Feb 2020||₩35.2t||₩1.2t||₩177.8b||60.5x|
|Fri, 08 Nov 2019||₩29.3t||₩1.0t||₩180.2b||73x|
|Thu, 01 Aug 2019||₩21.4t||₩994.5b||₩154.3b||54.5x|
|Sun, 05 May 2019||₩26.2t||₩1.0t||₩159.7b||62x|
|Wed, 06 Feb 2019||₩29.5t||₩1.0t||₩154.2b||40.8x|
Current Industry PE: Investors are more pessimistic on the industry, considering it's trading at a PE ratio of 26.3x which is lower than its 3-year average PE of 52.7x. It appears they believe that earnings will not grow as fast as they have historically.
Past Earnings Growth: The earnings for companies in the Life Sciences industry have grown 39% per year over the last three years, and revenues for these companies have grown 32% per year. This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Which industries have driven the changes within the South Korean Life Sciences industry?
|Clinical Research and Equipment||-6.12%|
Industry PE: Investors are most optimistic about the Clinical Research and Equipment industry even though it's trading below its 3-year average PE ratio of 52.7x. This is likely because analysts are expecting annual earnings growth of 17%, which is higher than its past year's earnings growth of 15% per year.
Forecasted Growth: Analysts are most optimistic on the Clinical Research and Equipment industry, expecting annual earnings growth of 17% over the next 5 years. This is roughly in line with its past earnings growth rate.
Which companies have driven the market over the last 7 days?
BioInfra Life Science
Eone Diagnomics Genome Center
PHARMA RESEARCH BIO